| __timestamp | Biogen Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 10337679 |
| Thursday, January 1, 2015 | 2113100000 | 18187286 |
| Friday, January 1, 2016 | 1947900000 | 24758063 |
| Sunday, January 1, 2017 | 1935500000 | 23666957 |
| Monday, January 1, 2018 | 2106300000 | 30099855 |
| Tuesday, January 1, 2019 | 2374700000 | 64947625 |
| Wednesday, January 1, 2020 | 2504500000 | 186363444 |
| Friday, January 1, 2021 | 2674300000 | 272611040 |
| Saturday, January 1, 2022 | 2403600000 | 358782000 |
| Sunday, January 1, 2023 | 2549700000 | 409864000 |
| Monday, January 1, 2024 | 2403700000 |
Unleashing insights
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Biogen Inc. and Intra-Cellular Therapies, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Biogen, a giant in the biotech sector, has consistently maintained high SG&A expenses, peaking in 2021 with a 38% increase from 2014. In contrast, Intra-Cellular Therapies, a smaller player, has seen a dramatic rise in SG&A expenses, skyrocketing by nearly 3,900% from 2014 to 2023. This surge reflects its aggressive market expansion and investment in new therapies. These trends highlight the differing strategies: Biogen's steady approach versus Intra-Cellular's rapid growth. As the industry evolves, these financial patterns offer insights into each company's priorities and market positioning.
Breaking Down SG&A Expenses: Johnson & Johnson vs Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: AstraZeneca PLC vs Biogen Inc.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Biogen Inc.
Selling, General, and Administrative Costs: argenx SE vs Biogen Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Selling, General, and Administrative Costs: Biogen Inc. vs Wave Life Sciences Ltd.
SG&A Efficiency Analysis: Comparing Biogen Inc. and Ligand Pharmaceuticals Incorporated
Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Catalent, Inc.
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends